On February 27, 2026, the US FDA approved three new indications for the growth hormone Sogroya (somapacitan) intended for children older than 2.5 years[2]. Sogroya is now indicated for children with idiopathic short stature, children born low for gestational age without return to normal growth by age 2 years, and children with growth failure associated with Noonan syndrome[1]. The main advantage of this drug is that it is administered once a week, which is an alternative to traditional daily injections and offers 313 injection-free days per year[2]. The approval is based on the REAL8 study, which demonstrated that Sogroya is as effective as daily growth hormone in all three indications[3]. The most common side effects occurred in at least 10% of cases and included respiratory tract infections, nasopharyngitis, ear infections, and diarrhea[3]. Novo Nordisk has previously applied to approve Sogroy for Turner syndrome as well, with a decision expected later in 2026[2].